Table 1.
N | R (95%CI) | k (95%CI) | *Prop80% (95%CI) | ⁎⁎Prop0% (95%CI) | ||
---|---|---|---|---|---|---|
Whole Period | All | 16471 | 0.47 (0.45–0.49) | 0.23 (0.22–0.25) | 13.3% (12.8%–13.9%) | 77.2% (76.3%–78.1%) |
0-19 | 847 | 0.36 (0.30–0.43) | 0.22 (0.17–0.29) | 12.1% (9.9%–14.6%) | 80.7% (76.8%–84%) | |
20-39 | 7647 | 0.41 (0.38–0.43) | 0.21 (0.19–0.23) | 12.1% (11.4%–12.9%) | 79.7% (78.4%–80.9%) | |
40-69 | 5832 | 0.52 (0.49–0.55) | 0.29 (0.26–0.32) | 15.4% (14.4%–16.3%) | 74.1% (72.6%–75.8%) | |
70- | 1996 | 0.62 (0.55–0.69) | 0.21 (0.18–0.24) | 13% (11.6%–14.5%) | 74.9% (72.1%–77.5%) | |
Phase1 | All | 2415 | 0.53 (0.48–0.58) | 0.21 (0.18–0.24) | 12.6% (11.4%–13.9%) | 76.9% (74.4%–79.1%) |
0-19 | 62 | 0.24 (0.11–0.45) | 0.42 (0.12–Inf) | 12.6% (5.4%–27.3%) | 82.6% (63.7%–92.4%) | |
20-39 | 762 | 0.35 (0.29–0.42) | 0.24 (0.18–0.33) | 12.4% (10%–15.3%) | 80.6% (76.3%–84.2%) | |
40-69 | 1233 | 0.57 (0.50–0.65) | 0.22 (0.19–0.27) | 13.3% (11.6%–15.3%) | 75.3% (71.6%–78.4%) | |
70- | 343 | 0.83 (0.62–1.06) | 0.20 (0.15–0.28) | 13.9% (10.7%–17.6%) | 72% (64.7%–78.3%) | |
Phase2 | All | 1738 | 0.37 (0.32–0.42) | 0.19 (0.16–0.23) | 11.2% (9.7%–12.9%) | 81.5% (78.8%–83.9%) |
0-19 | 44 | 0.2 (0.07–0.43) | 0.53 (0.08–Inf) | 11.8% (3.5%–26.4%) | 84.1% (64.9%–95.1%) | |
20-39 | 471 | 0.24 (0.17–0.31) | 0.16 (0.10–0.24) | 8.8% (6.2%–11.9%) | 86.4% (81.9%–90.4%) | |
40-69 | 823 | 0.44 (0.36–0.53) | 0.20 (0.15–0.26) | 11.9% (9.7%–14.5%) | 79.2% (74.8%–83%) | |
70- | 364 | 0.39 (0.29–0.5) | 0.24 (0.16–0.36) | 12.9% (9.5%–16.9%) | 79.3% (73.1%–84.7%) | |
Phase3 | All | 6397 | 0.50 (0.47–0.53) | 0.25 (0.23–0.27) | 13.9% (13.1%–14.9%) | 76% (74.5%–77.4%) |
0-19 | 443 | 0.45 (0.36–0.57) | 0.26 (0.18–0.38) | 14% (10.7%–18.1%) | 76.9% (70.5%–82.1%) | |
20-39 | 3795 | 0.47 (0.44–0.51) | 0.21 (0.19–0.24) | 12.5% (11.5%–13.6%) | 78% (76.1%–79.8%) | |
40-69 | 1625 | 0.58 (0.52–0.65) | 0.32 (0.27–0.38) | 16.5% (14.9%–18.5%) | 71.8% (68.6%–74.6%) | |
70- | 455 | 0.49 (0.39–0.59) | 0.34 (0.25–0.5) | 16.4% (13%–20.5%) | 73.8% (67.6%–79.1%) | |
Phase4 | All | 5921 | 0.44 (0.42–0.48) | 0.25 (0.23–0.28) | 13.7% (12.8%–14.7%) | 77.4% (75.8%–78.9%) |
0-19 | 298 | 0.27 (0.17–0.38) | 0.16 (0.09–0.28) | 9.1% (5.9%–13.6%) | 85.5% (78.9%–90.7%) | |
20-39 | 2619 | 0.36 (0.32–0.39) | 0.23 (0.19–0.27) | 12.1% (10.8%–13.6%) | 80.7% (78.5%–82.7%) | |
40-69 | 2151 | 0.48 (0.44–0.53) | 0.39 (0.33–0.46) | 17.3% (15.6%–19.2%) | 73.1% (70.3%–75.7%) | |
70- | 834 | 0.70 (0.58–0.82) | 0.19 (0.16–0.24) | 12.9% (10.9%–15.2%) | 74.6% (70.1%–78.5%) |
Prop80% is the proportion of cases responsible for 80% of all cases.
Prop0% is the proportion of cases that did not generate any secondary transmissions.